ARS Pharmaceuticals Joins Piper Sandler Healthcare Conference

ARS Pharmaceuticals Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York. CEO Richard Lowenthal and Chief Commercial Officer Eric Karas will join a fireside chat on December 3 at 2:30 pm ET. The management team will also hold one-on-one meetings with investors. A live webcast of the chat will be available on the company’s website, with a replay accessible for 90 days.

The Nasdaq Biotechnology Index closed up nearly 1.4%, closely mirroring the performance of the Dow Jones Industrial Average. Among the constituent stocks, Esperion rose 16.09%, ARS Pharmaceuticals rose 15.50%, Anavex Life Sciences rose 12.34%, Personalis rose 12.31%, Autolus Therapeutics rose 12.10%, and Aura Biosciences rose 11.09%. AC Immune fell 5.84%, LENZ Therapeutics fell 6.51%, and Cullinan Oncology LLC fell 8.82%

ARS Pharmaceuticals: Strategic Positioning and Market Potential for Neffy Justifies Buy Rating

William Blair analyst Lachlan Hanbury Brown maintains a Buy rating on ARS Pharmaceuticals due to strategic positioning and market potential for Neffy. Despite Anaphylm's adverse events, Neffy's differentiated profile and first-mover advantage suggest significant market opportunity. ARS's commercial initiatives and financial backing support Neffy's launch, with potential for increased prescriptions and revenue. Roth MKM also reiterates a Buy rating with a $30 price target.

ARS Pharmaceuticals Executives Conduct Major Stock Transactions

ARS Pharmaceuticals executives Brian Dorsey and Justin Chakma sold significant shares. Dorsey sold 21,828 shares for $190,049, retaining 10,789 shares. Chakma sold 166,380 shares for $1,476,147, now holding no shares.

ARS Pharmaceuticals COO Brian Dorsey Reports Sale of Common Shares

Brian Dorsey, COO of ARS Pharmaceuticals Inc., reported the sale of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system.